Press Releases

Oct 7, 2021

Phio Pharmaceuticals Presents New BRD4 Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

MARLBOROUGH, Mass., Oct. 7, 2021 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today presented new data with PH-894, Phio’s self-delivering RNAi compound targeting the bromodomain-containing protein 4 (BRD4) at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics. The data presented add to the growing body of evidence that BRD4 not only plays a role in tumor cells, but can also regulate T cell function and that PH-894 can reprogram T cells to provide enhanced immunotherapeutic activity.

Logo –

“The data we presented today at the AACR-NCI-EORTC meeting demonstrates silencing BRD4 with our INTASYL compound PH-894 has a significant impact on T cell function and phenotype promoting T cell activation and immunosuppression in the tumor microenvironment,” said Simon Fricker, Phio’s Vice President of R&D. “Our new data shows how BRD4 can regulate immune cells activity and therefore BRD4 silencing with PH-894 could become an important approach to treat cancer.”

In this study conducted in collaboration with the Karolinska Institutet in Sweden, it was shown that PH-894 resulted in a strong, concentration dependent and durable silencing of BRD4 in T cells, which in an in vivo study translated to pronounced and dose associated inhibition of tumor growth. These data demonstrate that Phio’s PH-894 INTASYL compound can reprogram T cells to provide enhanced immunotherapeutic activity.

“We are very excited by these data, which suggest that PH-894’s potency is not solely a consequence of its direct effect on tumor cells, but also its ability to reprogram and activate T cells to further boost the anti-cancer effect. As such, we are working hard on IND-enabling studies to bring this promising compound to the clinic,” continued Dr. Fricker.

Phio’s presentation detailing the data presented at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics titled, “Targeting BRD4 in T cells with self-delivering RNAi PH-894 for immunotherapy” will be made available on the “Investors – Events and Presentations” section of the Company’s website (click here).

About Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic platform. The Company’s efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor micro-environment. Our goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company’s website,

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “intends,” “believes,” “anticipates,” “indicates,” “plans,” “expects,” “suggests,” “may,” “would,” “should,” “potential,” “designed to,” “will,” “ongoing,” “estimate,” “forecast,” “target,” “predict,” “could” and similar references, although not all forward-looking statements contain these words. Forward-looking statements are neither historical facts nor assurances of future performance. These statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by the ongoing coronavirus pandemic, the development of our product candidates, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, results from our preclinical and clinical activities, the timing or likelihood of regulatory filings and approvals, our ability to manufacture and supply our product candidates for clinical activities and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption “Risk Factors” and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.

Contact Phio Pharmaceuticals Corp.

Investor Contact
Ashley R. Robinson
LifeSci Advisors

Cision View original content:

SOURCE Phio Pharmaceuticals Corp.